Literature DB >> 9056393

Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro.

D J Stone1, I Rozovsky, T E Morgan, C P Anderson, H Hajian, C E Finch.   

Abstract

This study examined the regulation of apolipoprotein E (apoE) by 17beta-estradiol (E2) in brain glia, using rats with regular ovulatory cycles as an in vivo model and cultured astrocytes and mixed glia as in vitro models. Two brain regions were examined which had demonstrated transient synaptic remodeling during the estrous cycle. In the hippocampal CA1 region and the hypothalamic arcuate nucleus, apoE mRNA was elevated at proestrus when plasma E2 was high and synaptic density was increasing. Both astrocytes and microglia contributed to this increase in apoE mRNA. In vitro, E2 treatment had no effect on apoE mRNA levels in monotypic cultures of either astrocytes or microglia. In contrast, mixed glial cultures responded to E2 with increased apoE mRNA and protein, suggesting that heterotypic cellular interactions are important in the brain response to estrogens. In situ hybridization in combination with cell-specific markers showed that E2 increased apoE mRNA levels in both astrocytes and microglia. These results, which are the first evidence of apoE mRNA localization to microglia in vivo and the control of apoE expression in brain cells by estrogens, are discussed in terms of the possible protective role of E2 in Alzheimer's disease and prior findings that emphasize the expression of apoE mRNA in astrocytes within the brain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056393     DOI: 10.1006/exnr.1996.6360

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  63 in total

Review 1.  Alzheimer's disease in man and transgenic mice: females at higher risk.

Authors:  R S Turner
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Presence of oestrogen receptor type beta in human retina.

Authors:  C Munaut; V Lambert; A Noël; F Frankenne; M Deprez; J M Foidart; J M Rakic
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

3.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

4.  The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption.

Authors:  Justin Legleiter; John D Fryer; David M Holtzman; Andtomasz Kowalewski
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

5.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

6.  Acute responses to estradiol replacement in the olfactory system of apoE-deficient and wild-type mice.

Authors:  Britto P Nathan; Michael Tonsor; Robert G Struble
Journal:  Brain Res       Date:  2010-05-04       Impact factor: 3.252

Review 7.  A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.

Authors:  Erin E Sundermann; Pauline M Maki; Jeffrey R Bishop
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

8.  Hormonal modulators of glial ABCA1 and apoE levels.

Authors:  Jianjia Fan; Yoko Shimizu; Jeniffer Chan; Anna Wilkinson; Ayaka Ito; Peter Tontonoz; Edie Dullaghan; Liisa A M Galea; Tom Pfeifer; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2013-09-02       Impact factor: 5.922

Review 9.  Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease.

Authors:  N C Inestrosa; M P Marzolo; A B Bonnefont
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

10.  Microsequencing of bovine cerebrospinal fluid apolipoproteins: identification of bovine apolipoprotein E.

Authors:  D L Puppione; W H Fischer; M Park; O S Gazal; G L Williams
Journal:  Lipids       Date:  1998-08       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.